drug · small molecule
inaxaplin
Phase 3updated 5mo agoby $VERX Vertex, Inc.🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Phase 2 3 (across all indications), with 2 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying inaxaplin
News(5)
- Lilly’s latest China drug deal; Immunovant’s setback in lupusLilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded a…biopharma_dive · 10d ago
- Vertex aims for broad kidney disease label ahead of key readout next yearVertex Pharmaceuticals reported that an experimental kidney disease drug called inaxaplin improved measures on a urine test in two different patient populations, raising optimism ahead of an upcomi…endpoints · 12d ago
- Vertex opens up larger kidney disease opportunity with mid-stage readoutWhile Vertex is laser-focused on an upcoming FDA decision for povetacicept in immunoglobulin A nephropathy, the APOL1 inhibitor inaxaplin has demonstrated potential “best-in-class” data in a differ…biospace · 12d ago
- Vertex’s midstage data amplify kidney disease market opportunityVertex has reported positive phase 2b data for its kidney disease prospect inaxaplin, boosting its efforts to expand beyond the population targeted in a pivotal trial.fiercebiotech · 12d ago
- Vertex earnings get muted investor responseWhile overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug Journavx missed analyst estimates by double-digit percentages.biopharma_dive · 5mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that